not used title

not used title

To maintain our position as the world’s top biopharmaceutical innovator, the U.S. biopharmaceutical industry needs predictable and reliable intellectual property protections. Compulsory licensing abuse – along with price controls and other trade barriers – threatens to chip away at our foothold and erode the resources companies can invest in the next generation of medicines.

In certain instances, such as public health emergencies, trade partners may legally issue a compulsory license – through which a government permits the making, use, sale or importation of patented pharmaceuticals without the patent-holder’s permission. However, some emerging economies are using the threat of compulsory licensing as a negotiating tool to strong-arm American companies and tip the scales. Others are issuing compulsory licenses even when globally-accepted standards are not met.

For example, the Indian government has long sought compulsory licenses to promote local production at the expense of U.S. manufacturers and workers. In one instance, India granted a compulsory license to a homegrown generic drug-maker for the production and sale of a patented oncology medicine in part because it was not manufactured in India. Meanwhile, India’s domestic pharmaceutical industry wins out – total sales for Indian generic drug companies continue to see double digit growth– while U.S. companies are harmed and 4.5 million jobs are put at risk.

Yet despite these abuses, studies have actually proven that compulsory licensing is an ineffective and unsustainable tactic. Rather, voluntary licensing and drug donation have long produced improved health outcomes and increased access without undermining the global supply chain or flouting international trade law. In fact, one obligation under international law requires that, prior to issuing a compulsory license, the acting government must first pursue a voluntary license with the patent-holder. However, certain U.S. trading partners continue to ignore these obligations and experiences by adopting laws and regulations that allow for compulsory licensing.

Indonesia is another example of such abuses. In 2016, the country adopted a new patent law that enables the government to grant compulsory licenses on broad public interest grounds and in circumstances where the drug is merely being manufactured outside its borders – violating terms of the WTO TRIPS Agreement. Further, since 2004, Indonesia has issued compulsory licenses on nine patented pharmaceutical products without even attempting to engage with the patent-holders on voluntary licenses or considering other more sustainable solutions.

For decades, international trade law has protected innovative ideas so they can thrive and propagate. Routine use of compulsory licenses is chipping away at this protection, and endanger U.S. biopharmaceutical innovators, as well as the economic output and jobs they support.

Jay Taylor

Jay Taylor is Executive Vice President of International Advocacy at PhRMA. Prior to Joining PhRMA, Jay was a partner at the international law firm, McDermott, Will & Emery, where he specialized in international trade policy, export controls and Foreign Corrupt Practices Act (FCPA) matters. Previously, Jay served as Associate General Counsel at the Office of the United States Trade Representative (USTR), where he managed and litigated numerous international trade disputes, and drafted and negotiated several free trade agreements. Mr. Taylor received his undergraduate degree from Princeton University, and a law degree from Tulane University.

Jay Taylor

Author Twitter

Bayh-Dole: The fuel for America’s innovation engine

September 2, 2026

Setting the record straight: 3 facts about drug patents

July 13, 2026

New PBM principles don't change the fundamental challenge: Access to lower-cost medicines

July 10, 2026

MFN could disrupt the affordable medicines patients depend on

June 18, 2026

Intellectual Property and Hatch-Waxman: A blueprint for American leadership and patient savings

June 2, 2026

Argentina sets course to enable innovation by rejecting failed patent rules

March 26, 2026

16 years later: How BPCIA continues to expand competition and lower costs

March 23, 2026

Key context is often missing from the debate over the Patent Trial and Appeal Board

March 20, 2026

MFN undermines U.S. biopharmaceutical innovation

February 25, 2026

Updated Analysis Underscores the Need for Brazil to Address Patent Backlogs

February 2, 2026

How post-approval innovation keeps delivering for patients

December 9, 2025

PhRMA calls on USTR to ensure foreign nations pay their fair share

November 4, 2025

Three things to know about Bayh-Dole: Innovation that pays off for taxpayers

October 9, 2025

Delivering breakthroughs and lower costs for patients

September 8, 2025

PBMs, not patents, are blocking access to lower-cost medicines

July 23, 2025

New report: How intellectual property drives U.S. innovation and biopharma's impact

June 30, 2025

New report: Post-approval innovation delivers substantial patient benefits

June 2, 2025

Tariffs on medicines would harm American competitiveness, industry and patients

May 7, 2025

The biopharmaceutical industry is one of the highest contributors to America’s economy among all manufacturers

April 30, 2025

USTR 2025 Special 301 Report corrects course

April 29, 2025

From sound to science: How IP powers innovation in music and hearing

April 25, 2025

How the IRA is impacting the generic drug market

April 8, 2025

3 myths critics get wrong about intellectual property

March 28, 2025

ICYMI: PhRMA submits comments to White House on artificial intelligence

March 17, 2025

Health care practitioners sound the alarm on middlemen-imposed barriers to patient care, need for policy change

March 13, 2025

Strong Trade Policies Protect American Workers and Biopharmaceutical Innovation

March 12, 2025

USTR remembers—three years later—that it announced a trade initiative with Europe

November 1, 2024

PhRMA submission calls for USTR to correct course on trade policy, enforcement

October 18, 2024

40 Years of Hatch-Waxman: How Can We Secure its Legacy?

September 24, 2024

40 Years of Hatch-Waxman: How does the Hatch-Waxman Act help patients?

September 23, 2024

40 Years of Hatch-Waxman: What is the Hatch-Waxman Act?

September 19, 2024

New research: American biopharmaceutical investment in R&D drives transformational innovation

September 16, 2024

Biden Administration report debunks myths around patent “evergreening” and “thickets”

September 3, 2024

What to know about the latest effort to break patents using a legally dubious avenue

August 21, 2024

WTAS: Proposed Unsubstantiated USPTO Rule Change is a Threat to American Innovation

August 12, 2024

Three things to know about the United Nations’ new HIV/AIDS report

July 31, 2024

No Region Left Behind: USTR expands its unambitious trade agenda to the western hemisphere

July 29, 2024

Case study: How seniors could face access disruptions because of the IRA’s price setting provisions

July 22, 2024

PhRMA launches education campaign on the benefits of America's IP system

June 26, 2024

ICYMI: Misaligned policies undermine patient access

June 6, 2024

ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes

May 30, 2024

Experts discuss the value of IP at Senate Judiciary Committee hearing

May 28, 2024

World Trade Week 2024: Time for a more ambitious U.S. trade agenda

May 23, 2024

World IP Day 2024: Supporting an innovative and sustainable future

April 26, 2024

Why won’t USTR strengthen medical supply chains with America’s allies?

April 25, 2024

3 Takeaways from POLITICO’s Health Care Summit

April 3, 2024

International meetings hold big implications for Americans and our innovation ecosystem

February 26, 2024

Proposed march-in framework would chill American innovation

February 7, 2024

PhRMA 2024 Special 301 submission: USTR needs to support American innovation, global access to medicines

January 31, 2024

Powering the next generation of therapies: A conversation with Astellas US President Mark Reisenauer

January 30, 2024

New poll: Americans agree that expanding the TRIPS waiver will harm U.S. global manufacturing and innovation leadership

January 29, 2024

What they are saying: Experts agree that proposed march-in framework would jeopardize innovation

January 25, 2024

The Biopharmaceutical Industry Still Needs Clarity from the FDA on Orange Book Listings

December 19, 2023

The White House continues to attack American innovation

December 15, 2023

Biden Administration’s Indo Pacific trade dialogue is a missed opportunity to bolster American exports, innovation

November 29, 2023

Misuse of march-in could stifle innovation

November 27, 2023

New analysis of patient access restrictions in the United Kingdom

November 21, 2023

WHO Pandemic Agreement offers opportunities and risks for American innovators

November 20, 2023

Word of the Month: The Bayh-Dole Act

November 8, 2023

ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference

November 6, 2023

PhRMA submission: USTR needs more ambition to combat unfair trade barriers

October 24, 2023

It’s PBMs, not patents, blocking competition 

September 14, 2023

What you need to know: COVID-19 public health emergency is over, but ideological attacks on IP remain

September 12, 2023

The Biden Administration has failed to advance an inclusive, worker-centered trade agenda

September 5, 2023

WTAS on reasonable pricing and public-private partnerships

August 8, 2023

Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation

July 26, 2023

Key considerations as Congress works towards PAHPA reauthorization

July 12, 2023

Reject efforts to undermine America’s R&D ecosystem

June 15, 2023

Four ways that America’s biopharmaceutical industry supports jobs and fuels economic growth

May 18, 2023

Setting the record straight on the Bayh-Dole Act and March-in

May 10, 2023

World IP Day 2023: Celebrating women leaders in innovation

April 26, 2023

What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary

April 13, 2023

New global analysis shows patient access challenges around the world

April 12, 2023

States can support access to medicine as COVID-19 Public Health Emergency ends

April 5, 2023

PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement

March 30, 2023

U.S. biopharmaceutical exports support jobs, innovation

March 20, 2023

Will the administration capitalize on the Indo-Pacific Economic Framework to drive medical innovation?

March 13, 2023

PhRMA submits comments to USPTO highlighting important role of patent system in medicine development

February 23, 2023

Minnesota lawmakers are letting PBMs off the hook, and threatening patients’ access to medicines

January 31, 2023

U.S. must address IP and market access barriers abroad to protect American innovation

January 31, 2023

Biden administration should prioritize innovation in U.S.-Taiwan Initiative on 21st-Century Trade

January 17, 2023

In their own words: Insured Americans support policy reforms that address access and affordability concerns

December 14, 2022

Expanding TRIPS waiver would jeopardize biopharmaceutical research and development

November 17, 2022

Six ways I-MAK is lying about biopharma patents

November 16, 2022

TRIPS waiver expansion risks public health

November 14, 2022

Expanding the WTO intellectual property waiver will hurt American jobs

November 9, 2022

PhRMA submission to USTR calls for urgent defense of American innovation abroad

November 1, 2022

The law driving technology transfer and fostering innovation

October 24, 2022

Don’t take anti-innovation, activist funded academics at their word

October 18, 2022

New report ignores benefits of patent system to innovation and patients

September 30, 2022

Partnerships are driving global COVID-19 treatment access

September 22, 2022

The dangers of expanding the TRIPS waiver

September 19, 2022

ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines

August 16, 2022

Patent policy changes proposed by USPTO and FDA would leave patients behind

July 22, 2022

ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies

July 15, 2022

CMS coverage decision restricts access to treatments for Alzheimer’s disease

June 22, 2022

Report finds PBMs are increasingly restricting patient access to medicines

May 25, 2022

Intellectual Property waiver on COVID-19 innovation is unnecessary and harmful

May 23, 2022

Biden Administration details inadequate protection of American intellectual property and foreign barriers to innovation abroad

April 29, 2022

PhRMA encourages Biden administration to pursue ambitious Indo-Pacific Economic Framework

April 13, 2022

Research and development continues long after a medicine is initially approved

February 1, 2022

Protecting U.S. innovation abroad to support economic and pandemic recovery

February 1, 2022

Legislation threatens patent protections and future innovation

January 12, 2022

Global COVID-19 vaccination matters now and for the future

November 29, 2021

New report highlights importance of IP-intensive manufacturing industries to the U.S. economy

November 1, 2021

PhRMA submission to 2022 National Trade Estimate Report underscores need for pro-innovation U.S. trade policy to combat COVID-19

October 29, 2021

Strengthening the WTOs global trade and health agenda

October 18, 2021

Patients and innovators lose if the government pursues ‘march-in’

September 7, 2021

Supporting country readiness to boost global vaccine access

August 12, 2021

Ensuring global vaccine equity requires eliminating trade and regulatory barriers

August 5, 2021

Increasing global access to vaccines by optimizing production

July 29, 2021

Dose sharing as a part of the COVID-19 global vaccine equity strategy

July 20, 2021

Promoting global vaccine equity while protecting innovation

July 15, 2021

New polling shows Americans are sounding the alarm on the TRIPS IP waiver

May 14, 2021

The Biden Administration allows politics to upend a pragmatic pandemic response

May 14, 2021

New report demonstrates development of new medicines relies on private sector expertise and investment

May 10, 2021

American leadership on innovation policy is essential to global health progress

May 4, 2021

Key excerpts: PhRMA submits comments to NIST in effort to safeguard intellectual property protections

April 9, 2021

Getting the 340B program back on track in 2021

March 10, 2021

Intellectual property is the key to vaccine development, manufacturing and technology sharing

March 5, 2021

The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing

February 12, 2021

Preserving U.S. innovation worldwide is more important than ever

January 29, 2021

New video: See how strong IP protections lead to stronger treatments for patients

November 9, 2020

U.S. trade policy must prioritize American biopharmaceutical innovation and patient access

November 2, 2020

Why the U.S. biopharmaceutical industry is leading the charge against COVID-19

September 30, 2020

Growth in innovative, value-based contracts holds promise for the health system and for patients

September 24, 2020

New Graphic: Public-Private collaboration fuels the U.S. biopharmaceutical ecosystem

September 16, 2020

Innovative contracts drive access for patients and value for the system

September 9, 2020

The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19

July 22, 2020

R&D Focus: 5 things to know about the biopharmaceutical research ecosystem

July 13, 2020

The latest: What they are saying: Importance of intellectual property protections to combat COVID-19

July 2, 2020

The latest: What they are saying: Intellectual property protections critical as we work to defeat COVID-19

June 5, 2020

IP Explained: Intellectual property system working to combat COVID-19

May 28, 2020

What they are saying: Intellectual property protections are critical as we work to defeat COVID-19

May 4, 2020

The continued imperative to protect U.S. innovation worldwide

April 29, 2020

ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements

April 20, 2020

PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs

March 3, 2020

Addressing barriers that inhibit value-based contracts

February 21, 2020

IP Explained: Four key takeaways from new Bayh-Dole white paper

February 19, 2020

Trump administration must defend and protect U.S. innovation

February 6, 2020

PhRMA submission to 2020 National Trade Estimate Report: Urgent action required to protect U.S. biopharmaceutical innovation

November 8, 2019

IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy

November 4, 2019

New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country

November 4, 2019

IP Explained: FACT CHECK: March-In Authority and the Bayh-Dole Act

October 9, 2019

IP Explained: Four things to know about the Bayh-Dole Act

September 13, 2019

Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important

September 4, 2019

IP Explained: Understanding biopharmaceutical innovation

July 30, 2019

IP Explained: Why IP protections are important for biologic medicines

July 18, 2019

Setting the record straight on international reference pricing

July 16, 2019

IP Explained: What is Section 101 and why reforms are needed

June 26, 2019

IP Explained: How Hatch-Waxman successfully balances affordability and innovation

May 22, 2019

World Trade Month: How we can expand world-class pro-innovation standards

May 22, 2019

IP Explained: Myth vs. fact about strong patent protections in the biopharmaceutical industry

May 2, 2019

IP Explained: What they are saying on the importance of strong intellectual property protections

April 24, 2019

IP Explained: Why patents are so critical to biopharmaceutical innovation

April 16, 2019

Fact Check: How the Part B International Pricing Index model threatens patient access

March 29, 2019

New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid

March 20, 2019

New report: Using march-in authority would jeopardize U.S. innovation

March 19, 2019

Special 301 submission calls for a level playing field for American innovators

March 13, 2019

Fact Check: Biologics, regulatory data protection and the United States-Mexico-Canada Agreement

February 27, 2019

PhRMA comments to administration on Medicare Part D proposed rule

January 25, 2019

ICYMI: New study reinforces dangers of proposed IPI model

January 15, 2019

Groups sound the alarm on administration’s new Part B proposal

November 14, 2018

4 things you need to know about the administration’s latest Part B proposal

November 5, 2018

PhRMA submission to the 2019 National Trade Estimate Report urges action to protect U.S. biopharmaceutical innovation

November 2, 2018

Five myths about global efforts to combat tuberculosis

September 20, 2018

How much do you know about Medicare Part B?

July 31, 2018

Here’s how America’s biopharmaceutical companies lead the way in development of innovative new medicines

July 25, 2018

ICER’s budget impact threshold: Sounding a false alarm on affordability and access

July 24, 2018

PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs

July 16, 2018

Event next week: Supporting the next generation of lifesaving medicines

July 12, 2018

Guest post: Excellent care for LGBTQ patients requires cultural humility and specific medical knowledge

June 28, 2018

Celebrating U.S. innovation as USPTO issues the 10 millionth patent

June 19, 2018

New analysis shows that more medicines worldwide are available to U.S. patients

June 5, 2018

New analysis shows that HTA organizations may frequently restrict access to cancer treatments

June 1, 2018

New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B

May 31, 2018

Event tomorrow: Improving patient access to lifesaving medicines

May 22, 2018

To continue to drive the innovation economy and exports, American biopharmaceutical sector depends on fair trade agreements

May 10, 2018

Event tomorrow: Making the biopharmaceutical supply chain work for patients

May 2, 2018

PPA celebrates 13 years of helping patients access their medicines

April 5, 2018

What is inter partes review and why does it matter?

March 16, 2018

Copay coupons can help ease patients’ out-of-pocket costs

February 16, 2018

PhRMA launches new consumer-facing Let’s Talk About Cost website

January 24, 2018

Supporting opportunities for enhanced competition in the marketplace

November 22, 2017

Video: What is a results-based contract?

November 13, 2017

How much are hospitals marking up the price of medicines? The answer may surprise you.

October 17, 2017

Biopharma leads sustained economic growth driven by IP-intensive industries

September 26, 2017

Opportunities to build upon enhanced competition for medicines in the marketplace

July 27, 2017

Poll respondents appreciate economic benefits of innovation and call for more protections

July 11, 2017

As U.S. looks to modernize NAFTA, strong enforcement of existing obligations should be a top priority

June 13, 2017

Foreign government price setting by any name harms innovation and access to medicines

June 6, 2017

Government-imposed price controls threaten innovation and access

May 9, 2017

ICYMI: Ubl weighs in on how fair trade protects US biopharmaceutical innovation

May 5, 2017

Illegal trade barriers discriminate against U.S. innovators

May 2, 2017

Trading fair means upholding the law: A focus on patents

April 18, 2017

Enforcing unmet trade obligations protects U.S. innovation

April 11, 2017

NAFTA tribunal fails to rule on Canada’s patent utility doctrine

April 4, 2017